- JAK inhibitor, a new player for treatment-refractory microscopic colitis
-
Druez A, Travis S, Rahier JF
- KMID: 2544764
- Intest Res.
- 2023 Jul;21(3):411-412.
- doi: 10.5217/ir.2023.00030
-
- CITED
-
- Close
- SHARE
-
- Close
- What's app? Electronic health technology in inflammatory bowel disease
-
Walsh A, Travis S
- KMID: 2417648
- Intest Res.
- 2018 Jul;16(3):366-373.
- doi: 10.5217/ir.2018.16.3.366
Electronic health (eHealth) data collection is increasingly used in many chronic illnesses, to track pattern of disease. eHealth systems have the potential to revolutionize care. Inflammatory bowel disease (IBD) is... -
- CITED
-
- Close
- SHARE
-
- Close
- Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions
-
Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, Byrne MF
- KMID: 2544752
- Intest Res.
- 2023 Jul;21(3):283-294.
- doi: 10.5217/ir.2023.00020
Inflammatory bowel disease encompasses Crohn’s disease and ulcerative colitis and is characterized by uncontrolled, relapsing, and remitting course of inflammation in the gastrointestinal tract. Artificial intelligence represents a new era... -
- CITED
-
- Close
- SHARE
-
- Close
- Improving the quality of care for inflammatory bowel disease
-
Ye BD, Travis S
- KMID: 2438442
- Intest Res.
- 2019 Jan;17(1):45-53.
- doi: 10.5217/ir.2018.00113
Great strides have been achieved in the development of quality-of-care measures and standards for inflammatory bowel disease (IBD) over the last decade. The central structural component of care in IBD... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis
-
Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, Geddes J, Goodwin G, Collins G, Travis S, Peters M
- KMID: 2454745
- Intest Res.
- 2019 Jul;17(3):365-374.
- doi: 10.5217/ir.2018.00173
BACKGROUND/AIMS: TrueColours ulcerative colitis (TCUC) is a comprehensive web-based program that functions through email, providing direct links to questionnaires. Several similar programs are available, however patient perspectives are unexplored. METHODS: A... -
- CITED
-
- Close
- SHARE
-
- Close
- Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
-
Wu KC, Ran ZH, Gao X, Chen M, Zhong J, Sheng JQ, Kamm MA, Travis S, Wallace K, Mostafa NM, Shapiro M, Li Y, Thakkar RB, Robinson A
- KMID: 2425288
- Intest Res.
- 2016 Apr;14(2):152-163.
- doi: 10.5217/ir.2016.14.2.152
BACKGROUND/AIMS: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS: Thirty, adult Chinese patients with CD... -
- CITED
-
- Close
- SHARE
-
- Close
